Dr. Chelsea Amstuz is Director of Analytical Sciences in Cell Therapy Development at Bristol Myers Squibb. She focused on the molecular virology of lentiviruses in her PhD study and has spent the past decade working in cell therapy field in Seattle, WA. She leads teams that create analytical tools and assess analytical technology with a focus on enabling agile lentiviral vector and AAV process development and a robust understanding of vector biological attributes and impact. She is passionate about fully connecting vector molecular design and manufacturing process to vector attributes and function to therapeutic T cell attributes and patient outcomes.